We have observed
12 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after September 22, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
BICYCLIC PYRIMIDONE COMPOUNDS
2,3-DIHYDROIMIDAZO[1,2-C]PYRIMIDIN-5(1H)-ONE COMPOUNDS USE AS LP-PLA INHIBITORS
NOVEL CRYSTAL FORM
2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1H)-ONE BASED LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) INHIBITORS
BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2
PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2
HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE
IMPROVED ANTI-SERUM ALBUMIN BINDING VARIANTS